ValiRx plc Market Cap ($3.05 Million)
Market Cap & Net Worth: ValiRx plc (VAL)
ValiRx plc market cap. ValiRx plc (LSE:VAL) has a market capitalization of $3.05 Million (£2.27 Million) as of November 3, 2026. Listed on the LSE stock exchange, this UK-based company holds position #29434 globally and #589 in its home market, demonstrating a 21.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ValiRx plc's stock price £0.17 by its total outstanding shares 742721072 (742.72 Million). Also see VAL operating cash flow for how efficiently the company converts equity into cash flow.
ValiRx plc Market Cap History (2015–2026)
ValiRx plc market cap history from 2015 to 2026. Data shows change from $2.84 Trillion to $169.56 Million (-59.03% CAGR). Check VAL stock price for real-time trading data and today's change.
Index Memberships
ValiRx plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$998.29 Million | 0.31% | #67 of 722 |
Weight: ValiRx plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ValiRx plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ValiRx plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VAL shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
15529.69x
ValiRx plc's market cap is 15529.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.84 Trillion | $82.60K | -$2.12 Million | 34337438.25x | N/A |
| 2023 | $5.88 Billion | $9.60K | -$2.04 Million | 612989.56x | N/A |
| 2024 | $772.99 Million | $49.77K | -$1.92 Million | 15529.69x | N/A |
Competitor Companies of VAL by Market Capitalization
Companies near ValiRx plc in the global market cap rankings as of November 3, 2026. Also see balance sheet size of ValiRx plc for a full breakdown of the balance sheet.
Key companies related to ValiRx plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ValiRx plc (2015–2026)
Market capitalization of ValiRx plc from 2015 to today. Between 2015 and today, ValiRx plc's market cap moved from $2.84 Trillion to $ 169.56 Million, with a yearly change of -59.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | £169.56 Million | -49.25% |
| 2025 | £334.13 Million | -56.77% |
| 2024 | £772.99 Million | -86.86% |
| 2023 | £5.88 Billion | -57.86% |
| 2022 | £13.96 Billion | -61.38% |
| 2021 | £36.16 Billion | +85.90% |
| 2020 | £19.45 Billion | +30.00% |
| 2019 | £14.96 Billion | -85.45% |
| 2018 | £102.86 Billion | -81.14% |
| 2017 | £545.46 Billion | -16.67% |
| 2016 | £654.55 Billion | -76.92% |
| 2015 | £2.84 Trillion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ValiRx plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.05 Million USD |
| MoneyControl | $3.05 Million USD |
| MarketWatch | $3.05 Million USD |
| marketcap.company | $3.05 Million USD |
| Reuters | $3.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more